(Q36341730)

13 August 2017

1 reference

title

Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again (English)

1 reference

13 August 2017

1 reference

1 reference

5

Simon Mallal

1 reference

13 August 2017

Andri Rauch

4

1 reference

ORCID Public Data File 2021

author name string

Annalise Martin

series ordinal

1

1 reference

PubMed ID

16354121

13 August 2017

David Nolan

series ordinal

2

1 reference

PubMed ID

16354121

13 August 2017

Coral-Ann Almeida

series ordinal

3

1 reference

13 August 2017

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

1

1 reference

13 August 2017

15-23

1 reference

Abacavir hypersensitivity reaction

13 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Hypersensitivity related to abacavir in two members of a family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Risk factor analysis of hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Cytokine gene expression occurs more rapidly in stimulated peripheral blood mononuclear cells from human immunodeficiency virus-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Comparison of serum and cell-specific cytokines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Cytokine measurement techniques for assessing hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Molecular aspects of drug recognition by specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Haptenation of sulfonamide reactive metabolites to cellular proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

An overview of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

T helper type-2 cytokine responses: potential therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Th(1)/Th(2) responses to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Type 1/Type 2 immunity in infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Anti-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

HLA-B*5701 and abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.1.15

21 January 2018

Identifiers

DOI

10.2217/14622416.7.1.15

1 reference

13 August 2017

1 reference

PubMed ID

16354121